In Conversation

Switzerland Pharma Report June 2021
Latest Reports
Switzerland Pharma Report June 2021
- 2021
Switzerland continues to hold its own as a focal point for innovation and discovery in global medical science and ranks very highly on the radar of both Big Pharma and the international biotech community alike. As well as Switzerland’s continuing relevance to the European and global pharma industry, pharma is truly at the core of the Swiss economy, generating a full 5.4 percent of the country’s GDP, a number which rises to 9.2 percent when indirect effects are factored in. Moreover, the industry now accounts for a massive 45 percent of Switzerland’s total exports. This exclusive and wide-ranging new…
Switzerland Pharma Report February 2021
Latest Reports
Switzerland Pharma Report February 2021
- 2021
Switzerland, long held up as an innovation powerhouse able to hold its own against the considerably larger neighbouring life science markets of France and Germany, has, in some respects, found the going tougher of late. The country’s domestic drug market has been enduring a sticky patch and could only muster a modest growth rate of 2.8 percent in 2020 as policymakers grappled with issues more familiar to the rest of the continent such as cost-containment. Nonetheless, the country’s life science companies continue to achieve global acclaim and attract the attention of investors the world over.   As one of…
Norway Pharma Report 2021
Latest Reports
Norway Pharma Report 2021
- 2021
A bastion of equality with high levels of healthcare spending, excellent research and universities, a global commitment to improving health outcomes, and a deeply entrenched digital footprint, Norway is full of potential as a life sciences investment destination. This potential, however, has largely remained untapped until now, as the country has focused on its more established oil & gas and fishing industries. Without true governmental support, the Norwegian life sciences industry has been somewhat neglected, with clinical trials numbers declining in recent years and multinational companies feeling hesitant about the market access situation for their most innovative treatments. Nevertheless,…
Belgium Pharma Report 2020
Latest Reports
Belgium Pharma Report 2020
- 2020
This exclusive new report examines how Belgium has been able to establish itself as the ‘Pharma Valley of Europe’, famed for the quality and breadth of its medical research, the scale and complexity of its manufacturing infrastructure, and its multilingual, highly skilled, and industry savvy talent pool. It also looks at the wide variety of pharma multinationals who have chosen to situate regional headquarters, strategic hubs, as well as R&D and manufacturing sites in the country. Other topics covered include how the country’s domestic market has evolved since the 2015 ‘Pact for the Future’ between industry and government, the…
Romania Pharma Report May 2020
Latest Reports
Romania Pharma Report May 2020
- 2020
Following a battering by the 2008 global financial crisis and the austerity policies the country was forced to implement, Romania’s economy has rebounded well over the past few years, allowing the oft-overlooked Eastern European country to top the European Union table with enviable economic growth rates of around three to four percent over the past couple of years. However, this cheery picture does not extend to the healthcare industry, which has suffered through nearly two decades of chronic underinvestment as well as a debilitating instability in leadership. Stakeholders across the entire healthcare spectrum in the country – from government…
Czech Republic Pharma Report April 2020
Latest Reports
Czech Republic Pharma Report April 2020
- 2020
Home to a USD 3.38 billion pharma market, one of Central and Eastern Europe’s most high-performing healthcare systems, and one of the region’s leading economies, the Czech Republic’s healthcare and life sciences market is fast closing the gap on its Western European equivalents. A traditionally tightly regulated domestic market is undergoing reform, and a more amenable administration is putting in place a system more conducive to the latest medical innovations. Notable progress has been made in the fields of preventative medicine, cutting-edge oncology treatments, and orphan drugs. However, the country’s reference pricing system, whereby reimbursement is set based on…
Hungary Pharma Report 2020
Latest Reports
Hungary Pharma Report 2020
- 2020
In line with its status as one of Europe’s most dynamic economies, Hungary is aiming to boost both its life sciences industry and the level of healthcare it provides to its citizens. Year-on-year GDP growth stood at 4.8 percent in 2019, driven on by a burgeoning domestic pharmaceuticals industry which accounted for 7.5 percent of the total economy and 4.9 percent of all exports. This report examines how Hungary is aiming to capitalise on its rich expertise in pharmacology, with local champions such as Egis and Gedeon Richter rapidly internationalising, clinical research activities on the up, and increasingly innovative…
Sweden Pharma Report December 2019
Latest Reports
Sweden Pharma Report December 2019
- 2019
Belying its small size, the Nordic nation of Sweden punches well above its weight in scientific innovation. Nowhere is this Swedish spirit of innovation more keenly felt than in the country’s healthcare and life sciences industry. As the nation that introduced some of the most impactful healthcare inventions of the 20th century, Sweden and its USD 4.8 billion pharma market are at the forefront of a number of key industry trends.   Topics covered in this report include the unique spirit of collaboration that pervades the nation’s healthcare and life sciences industry, how Sweden is aiming to regain its place…
Spain Pharma Report September 2019
Latest Reports
Spain Pharma Report September 2019
- 2019
Building on the topics covered in our March 2019 report, this latest edition of Healthcare & Life Sciences Review Spain takes a closer look at the broader Spanish life sciences value chain. With the Iberian nation enjoying an economic rebound, pharmaceutical multinationals are once again seeing Spain as a favourable investment destination, taking into account the country’s Swiss or German quality levels at southern European prices. Indeed, recent years have seen big ticket infrastructural investments in Spanish manufacturing plants from the likes of Pfizer, Takeda and Bayer. This trend is also prevalent in the medical devices sphere, with Becton…
France Pharma Report June 2019
Latest Reports
France Pharma Report June 2019
- 2019
Following on from our March 2019 report, this latest issue of Healthcare & Life Sciences Review France takes a closer look at the wider French life sciences value chain and the spirit of innovation and reform sweeping the nation.   A reform-minded and business-oriented administration under President Emmanuel Macron has already made significant progress, with foreign direct investment up by 31 percent in the past year. Life sciences have been placed at the heart of France’s new national industrial strategy, with significant healthcare reform already underway.   Furthermore, national champions such as Servier, Pierre Fabre and Ipsen are striking…

Focus on United Kingdom

Read more from United Kingdom >>

Focus on Austria

Read more from Austria >>

Focus on Germany

Read more from Germany >>

Focus on Switzerland

Read more from Switzerland >>

We use cookies to ensure that we give you the best experience on our site. For more info click here